Posted by Michael Wonder on 28 Oct 2019
Heron Therapeutics announces FDA acceptance of new drug application resubmission for HTX-011 for management of post-operative pain
28 October 2019 - FDA sets prescription drug user fee act goal date of 26 March 2020.
Heron Therapeutics today announced that the U.S. FDA has accepted its new drug application resubmission for HTX-011, an investigational agent for the management of postoperative pain.
